Those with any skin toxicity had an ORR of 25.8% in the combination arms and 13% in the cetuximab-alone arm. [22] In the study conducted by Lenz et al, the severity of rash was strongly related to ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

Erbitux (cetuximab) is a prescription drug that’s used to treat certain types of cancer. The drug comes as a solution that’s given through a vein by a healthcare professional. It’s usually ...

The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group receiving only supportive care. Rash was seen in 255 of the patients treated with cetuximab.

In a continuously evolving landscape, the Erbitux global market showcases a promising trajectory. According to data, the prospects of Erbitux seem to be heading towards a bright future.